FPF vs JPM
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
The deterministic health profile is critically weak, headlined by a Piotroski F-Score of 1/9, indicating severe fundamental deterioration or structural misalignment with corporate health metrics. FPF is currently trading at a significant premium ($18.44) relative to its calculated intrinsic value of $13.79. This valuation gap, combined with a 0/100 technical trend and a high payout ratio of 83.76%, suggests the fund is overvalued and facing negative momentum despite its attractive dividend yield.
JPM exhibits a concerning Piotroski F-Score of 2/9, indicating weak short-term fundamental health, and currently trades at a significant premium to both its Graham Number ($239.11) and Intrinsic Value ($140.07). While the company maintains a strong ROE of 16.13% and dominant market positioning, negative YoY earnings growth (-3.60%) and bearish insider activity from the CEO and CFO signal internal caution. The stock's current price of $313.68 suggests the market is pricing in a growth premium that is not currently supported by the deterministic health or value metrics.
Compare Another Pair
Related Comparisons
FPF vs JPM: Head-to-Head Comparison
This page compares First Trust Intermediate Duration Preferred & Income Fund (FPF) and JPMorgan Chase & Co. (JPM) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.